An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis

PHASE2TerminatedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

August 6, 2019

Primary Completion Date

December 9, 2020

Study Completion Date

December 9, 2020

Conditions
Generalized Myasthenia Gravis
Interventions
DRUG

M281

M281 injection administered as intravenous infusion

Trial Locations (54)

1070

Momenta Investigational Site, Brussels

2650

Momenta Investigational Site, Antwerp

3000

Momenta Investigational Site, Leuven

10021

Momenta Investigational Site, New York

20014

Momenta Investigational Site, Donostia / San Sebastian

20133

Momenta Investigational Site, Milan

27607

Momenta Investigational Site, Raleigh

27710

Momenta Investigational Site, Durham

28007

Momenta Investigational Site, Madrid

28040

Momenta Investigational Site, Madrid

28207

Momenta Investigational Site, Charlotte

30912

Momenta Investigational Site, Augusta

32751

Momenta Investigational Site, Maitland

33487

Momenta Investigational Site, Boca Raton

33713

Momenta Investigational Site, St. Petersburg

33952

Momenta Investigational Site, Port Charlotte

37075

Momenta Investigational Site, Göttingen

38106

Momenta Investigational Site, Cordova

40225

Momenta Investigational Site, Düsseldorf

41013

Momenta Investigational Site, Seville

43210

Momenta Investigational Site, Columbus

45267

Momenta Investigational Site, Cincinnati

46026

Momenta Investigational Site, Valencia

48149

Momenta Investigational Site, Münster

51643

Momenta Investigational Site, Gummersbach

66205

Momenta Investigational Site, Fairway

78681

Momenta Investigational Site, Round Rock

78756

Momenta Investigational Site, Austin

80045

Momenta Investigational Site, Aurora

85013

Momenta Investigational Site, Phoenix

90015

Momenta Investigational Site, Cefalù

90048

Momenta Investigational Site, Los Angeles

92868

Momenta Investigational Site, Orange

94305

Momenta Investigational Site, Stanford

98125

Momenta Investigational Site, Messina

06511

Momenta Investigational Site, New Haven

02114

Momenta Investigational Site, Boston

02115

Momenta Investigational Site, Boston

02215

Momenta Investigational Site, Boston

08550

Momenta Investigational Site, New Brunswick

T6G 2G3

Momenta Investigational Site, Edmonton

N6A 5A5

Momenta Investigational Site, London

M5G 2C4

Momenta Investigational Site, Toronto

G1J 1Z4

Momenta Investigational Site, Québec

31-505

Momenta Investigational Site, Krakow

90-324

Momenta Investigational Site, Lodz

01-684

Momenta Investigational Site, Warsaw

01-868

Momenta Investigational Site, Warsaw

08035

Momenta Investigational Site, Barcelona

08041

Momenta Investigational Site, Barcelona

08036

Momenta Investigational Site, Barcelona

08907

Momenta Investigational Site, L'Hospitalet de Llobregat

B15 2TH

Momenta Investigational Site, Birmingham

S11 9NE

Momenta Investigational Site, Sheffield

Sponsors
All Listed Sponsors
lead

Momenta Pharmaceuticals, Inc.

INDUSTRY

NCT03896295 - An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis | Biotech Hunter | Biotech Hunter